PULMATRIX, INC. Proceeds from Issuance of Convertible Preferred Stock
PULMATRIX, INC. (PULM) reported Proceeds from Issuance of Convertible Preferred Stock of $1.00 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2026-09-17
- PULMATRIX, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2026-06-30 was $0.00.
- PULMATRIX, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2026-03-31 was $1.00M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: S-4/A 6 month − S-4/A 3 month · filed 2026-09-17 | $1.00M S-4/A · filed 2026-09-17 |
| 2026-03-31 | $1.00M S-4/A · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |